secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001193125-23-140010
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3
--------------------------------------------------------------------------------

- Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.
- Fully prepaid $11.0M SVB loan in May 2023; now debt-free; restricted cash of $13.9M released.
- Interim clinical data from TCR-T Library Phase 1/2 trial expected Q3 2023; cryopreserved products manufactured.
- Amended Precigen license: eliminated all royalties and milestones; retained exclusive rights to TCRs using Sleeping Beauty.
- Cash $37.4M at March 31; expects cash into Q4 2023; 2023 operating outflows $35-40M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/0001193125-23-140010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/d459099d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-140010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer